<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Innocare Pharma Ltd. A — News on 6ix</title>
    <link>https://6ix.com/company/innocare-pharma-ltd-a</link>
    <description>Latest news and press releases for Innocare Pharma Ltd. A on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 00:37:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/innocare-pharma-ltd-a" rel="self" type="application/rss+xml" />
    <item>
      <title>InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-phase-iii-trial-of-orelabrutinib-for-sle</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-phase-iii-trial-of-orelabrutinib-for-sle</guid>
      <pubDate>Wed, 29 Apr 2026 00:37:00 GMT</pubDate>
      <description>BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the registrational Phase III clinical trial of novel BTK inhibitor orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This is a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating the efficacy and safety of</description>
    </item>
    <item>
      <title>InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability</guid>
      <pubDate>Thu, 23 Apr 2026 13:20:00 GMT</pubDate>
      <description>BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the past decade, InnoCare has achieved remarkable results. 2026 marks the beginning of the Company’s next golden decade of development. Driven by its outstanding performance in 2025, the Company continued its rapid progress in the first quarter of 2026, increasing its investment in innovation, commercial</description>
    </item>
    <item>
      <title>Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/preclinical-data-of-novel-b7-h3-adc-icp-b794-unveiled-at-2026-aacr-demonstrating-superior-anti-tumor-activity-and-safety</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/preclinical-data-of-novel-b7-h3-adc-icp-b794-unveiled-at-2026-aacr-demonstrating-superior-anti-tumor-activity-and-safety</guid>
      <pubDate>Tue, 21 Apr 2026 10:00:00 GMT</pubDate>
      <description>BEIJING, April 21, 2026 (GLOBE NEWSWIRE) -- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel B7-H3 targeted ADC ICP-B794. The research results were presented in the form of a poster at the AACR Annual Meeting (Abstract Code: LB355). ICP-B794 is a B7-H3 targeted ADC with a novel linker-payload. It demonstrated potent anti-tumor activity in preclinical tumor models and a significantly large</description>
    </item>
    <item>
      <title>InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-releases-2025-results-and-business-highlights-achieving-first-annual-profit</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-releases-2025-results-and-business-highlights-achieving-first-annual-profit</guid>
      <pubDate>Wed, 25 Mar 2026 13:04:00 GMT</pubDate>
      <description>BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025. 2025 marked InnoCare’s 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application (NDA) approvals, enhanced market penetration of its core produc</description>
    </item>
    <item>
      <title>InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-healthy-volunteer-dosed-in-clinical-trial-of-novel-vav1-degrader-icp-538-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-healthy-volunteer-dosed-in-clinical-trial-of-novel-vav1-degrader-icp-538-in-china</guid>
      <pubDate>Mon, 16 Mar 2026 01:40:00 GMT</pubDate>
      <description>BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administe</description>
    </item>
    <item>
      <title>InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocares-next-generation-trki-zurletrectinib-receives-priority-review-for-the-treatment-of-pediatric-patients-with-solid-tumors-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocares-next-generation-trki-zurletrectinib-receives-priority-review-for-the-treatment-of-pediatric-patients-with-solid-tumors-in-china</guid>
      <pubDate>Mon, 02 Mar 2026 02:03:00 GMT</pubDate>
      <description>BEIJING, March 01, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is</description>
    </item>
    <item>
      <title>InnoCare Announces Key Developments of Critical Clinical Studies</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-key-developments-of-critical-clinical-studies</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-key-developments-of-critical-clinical-studies</guid>
      <pubDate>Thu, 26 Feb 2026 03:56:00 GMT</pubDate>
      <description>BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials. The Company completed patient enrollment of a Phase III registrational clinical trial of BCL2 inhibitor mesutoclax (ICP-248) in combination with BTK inhibitor orelabrutinib for treatment</description>
    </item>
    <item>
      <title>InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-the-phase-iiiii-clinical-trial-of-novel-tyk2-inhibitor-soficitinib-for-chronic-spontaneous-urticaria-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-the-phase-iiiii-clinical-trial-of-novel-tyk2-inhibitor-soficitinib-for-chronic-spontaneous-urticaria-in-china</guid>
      <pubDate>Fri, 13 Feb 2026 02:21:00 GMT</pubDate>
      <description>BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU). Currently, patient enrollment has been completed in the Phase III registrational clinical trial of soficitinib for the treat</description>
    </item>
    <item>
      <title>InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-ind-approval-to-initiate-clinical-trial-of-vav1-degrader-icp-538-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-ind-approval-to-initiate-clinical-trial-of-vav1-degrader-icp-538-in-china</guid>
      <pubDate>Mon, 09 Feb 2026 02:43:00 GMT</pubDate>
      <description>BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD). This is the first VAV1 degrader approved to enter cl</description>
    </item>
    <item>
      <title>Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/study-results-of-novel-tyk2-inhibitor-soficitinib-in-patients-with-ad-published-by-jama-dermatology</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/study-results-of-novel-tyk2-inhibitor-soficitinib-in-patients-with-ad-published-by-jama-dermatology</guid>
      <pubDate>Thu, 29 Jan 2026 08:17:00 GMT</pubDate>
      <description>BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The journal concluded that soficitinib demonstrated a favorable safety profile and encouraging efficacy, supporting further development for AD. This is a double-blind, placebo-controlled, phase 2 randomized clinical trial aiming to evaluate the safety and efficacy of soficitinib for</description>
    </item>
    <item>
      <title>InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-nmpa-approval-of-a-phase-ii-clinical-trial-of-tyk2-inhibitor-icp-488-for-cutaneous-lupus-erythematosus</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-nmpa-approval-of-a-phase-ii-clinical-trial-of-tyk2-inhibitor-icp-488-for-cutaneous-lupus-erythematosus</guid>
      <pubDate>Tue, 23 Dec 2025 10:00:00 GMT</pubDate>
      <description>BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a phase II clinical trial of its novel TYK2 inhibitor ICP-488 for the treatment of cutaneous lupus erythematosus (CLE). ICP-488 is an ora</description>
    </item>
    <item>
      <title>InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-approval-of-phase-iiiii-clinical-trial-of-novel-tyk2-inhibitor-soficitinib-for-chronic-spontaneous-urticaria-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-approval-of-phase-iiiii-clinical-trial-of-novel-tyk2-inhibitor-soficitinib-for-chronic-spontaneous-urticaria-in-china</guid>
      <pubDate>Thu, 18 Dec 2025 01:48:00 GMT</pubDate>
      <description>BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU). Sofi</description>
    </item>
    <item>
      <title>Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/zenas-biopharmas-partner-innocare-pharma-announces-achievement-of-primary-endpoint-in-phase-2b-study-of-orelabrutinib-a-btk-inhibitor-for-systemic-lupus-erythematosus</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/zenas-biopharmas-partner-innocare-pharma-announces-achievement-of-primary-endpoint-in-phase-2b-study-of-orelabrutinib-a-btk-inhibitor-for-systemic-lupus-erythematosus</guid>
      <pubDate>Mon, 15 Dec 2025 12:05:00 GMT</pubDate>
      <description>- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in all territories outside Greater China and Southeast Asia, in October 2025 license agreement with InnoCare – WALTHAM, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” o</description>
    </item>
    <item>
      <title>InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-achievement-of-primary-endpoint-in-phase-iib-study-of-orelabrutinib-for-sle-and-approval-of-phase-iii-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-achievement-of-primary-endpoint-in-phase-iib-study-of-orelabrutinib-for-sle-and-approval-of-phase-iii-clinical-trial</guid>
      <pubDate>Sun, 14 Dec 2025 09:49:00 GMT</pubDate>
      <description>BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also received approval from the Center for Drug Evaluation (CDE) to conduct a phase III registrational clinical trial. Orelabrutinib d</description>
    </item>
    <item>
      <title>InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-approval-of-the-next-generation-trk-inhibitor-zurletrectinib-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-approval-of-the-next-generation-trk-inhibitor-zurletrectinib-in-china</guid>
      <pubDate>Thu, 11 Dec 2025 11:03:00 GMT</pubDate>
      <description>BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received approval from the China National Medical Products Administration (NMPA) for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions. In the registrational clinical trial for patients with NTRK fusion-positive solid tum</description>
    </item>
    <item>
      <title>Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/over-20-studies-of-innocares-orelabrutinib-presented-at-the-67th-annual-meeting-of-the-american-society-of-hematology-ash</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/over-20-studies-of-innocares-orelabrutinib-presented-at-the-67th-annual-meeting-of-the-american-society-of-hematology-ash</guid>
      <pubDate>Wed, 10 Dec 2025 01:22:00 GMT</pubDate>
      <description>BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including marginal zone lymphoma (MZL), mantle cell lymphom</description>
    </item>
    <item>
      <title>Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/latest-data-of-innocares-novel-bcl2-inhibitor-presented-at-the-67th-annual-meeting-of-the-american-society-of-hematology-ash</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/latest-data-of-innocares-novel-bcl2-inhibitor-presented-at-the-67th-annual-meeting-of-the-american-society-of-hematology-ash</guid>
      <pubDate>Tue, 09 Dec 2025 02:04:00 GMT</pubDate>
      <description>BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of its novel BCL2 inhibitor, Mesutoclax (ICP-248), were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Mesutoclax demonstrated remarkable efficacy and a favorable safety profile in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (M</description>
    </item>
    <item>
      <title>InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-the-global-phase-ii-clinical-trial-of-tyk2-inhibitor-soficitinib-for-treatment-of-prurigo-nodularis</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-the-global-phase-ii-clinical-trial-of-tyk2-inhibitor-soficitinib-for-treatment-of-prurigo-nodularis</guid>
      <pubDate>Fri, 28 Nov 2025 01:55:00 GMT</pubDate>
      <description>BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-ce</description>
    </item>
    <item>
      <title>InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-clinical-trial-of-novel-adc-icp-b794-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/innocare-announces-first-patient-dosed-in-clinical-trial-of-novel-adc-icp-b794-in-china</guid>
      <pubDate>Fri, 31 Oct 2025 00:30:00 GMT</pubDate>
      <description>BEIJING, Oct. 30, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of its novel B7-H3 targeted ADC, ICP-B794, in China. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures pre</description>
    </item>
    <item>
      <title>Latest Data of InnoCare&apos;s Zurletrectinib Orally Presented at SIOP 2025</title>
      <link>https://6ix.com/company/innocare-pharma-ltd-a/news/latest-data-of-innocares-zurletrectinib-orally-presented-at-siop-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/innocare-pharma-ltd-a/news/latest-data-of-innocares-zurletrectinib-orally-presented-at-siop-2025</guid>
      <pubDate>Thu, 30 Oct 2025 03:51:00 GMT</pubDate>
      <description>BEIJING, Oct. 29, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data of its next generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors. The data from the phase I/II clinical trial has been released at the Congress of International Society of Paediatric Oncology (SIO</description>
    </item>
  </channel>
</rss>